STOCK TITAN

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Kala Pharmaceuticals (NASDAQ:KALA), a biopharmaceutical firm specializing in ocular therapies, will report its second quarter 2021 financial results on August 5, 2021. The company will also host a conference call at 8:00 a.m. ET to discuss the results and provide a business update. Kala's products include EYSUVIS for dry eye disease and INVELTYS for post-operative inflammation. The company leverages its proprietary AMPPLIFY mucus-penetrating particle technology to enhance drug delivery.

Positive
  • Kala has developed innovative therapies for eye diseases, leveraging its unique AMPPLIFY technology.
  • The upcoming earnings call may provide insights into the company's financial health and future plans, potentially positively impacting investor sentiment.
Negative
  • None.

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 3852499. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:
Jill Steier
Jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200 


FAQ

When will Kala Pharmaceuticals report its Q2 2021 financial results?

Kala Pharmaceuticals will report its second quarter 2021 financial results on August 5, 2021.

What is the conference call ID for Kala Pharmaceuticals' financial results discussion?

The conference call ID for Kala Pharmaceuticals' financial results discussion is 3852499.

What therapies does Kala Pharmaceuticals offer?

Kala Pharmaceuticals offers EYSUVIS for dry eye disease and INVELTYS for post-operative inflammation.

What time is the earnings call for Kala Pharmaceuticals?

The earnings call for Kala Pharmaceuticals is scheduled for 8:00 a.m. ET on August 5, 2021.

KALA BIO, Inc.

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Stock Data

38.08M
4.29M
5.14%
48.13%
0.81%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ARLINGTON